Rivoglitazone Hydrochloride PPARγ Agonist Insulin Sensitizer Treatment of Diabetes

被引：1
|
作者：
Davies, S. [1 ]
Castaner, R. [1 ]
Bolos, J. [1 ]
机构：
[1] Prous Sci, Barcelona 08025, Spain
来源：
DRUGS OF THE FUTURE | 2008年 / 33卷 / 11期
关键词：
CI-1037; CS-011; DE-101; R-106056;
D O I：
10.1358/dof.2008.033.011.1278754
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The complex metabolic disorder type 2 diabetes is a leading cause of morbidity and mortality worldwide and thus a health and economic burden. Daiichi Sankyo, has developed a new thiazolidinedione candidate for the treatment of type 2 diabetes, rivoglitazone hydrochloride (CS-011). In vitro, rivoglitazone demonstrates increased agonist activity at the peroxisome proliferator-activated receptor PPAR gamma compared to rosiglitazone, with in vivo and clinical studies confirming its enhanced antidiabetic activity compared with other thiazolidinediones. Rivoglitazone is currently undergoing phase II/III clinical development for the treatment of type 2 diabetes.
引用
收藏
页码：926 / 931
页数：6
相关论文
共 50 条
  • [21] The PPARα agonist fenofibrate does not improve insulin sensitivity in type 2 diabetes in man:: a randomised controlled trial
    Black, N.
    Ennis, C. N.
    Young, I. S.
    Hunter, S. J.
    Atkinson, B.
    Bell, P. M.
    DIABETOLOGIA, 2007, 50 : S321 - S322
  • [22] Insulin sensitizers: PPAR gamma agonist or an alternate pathway.
    Lohray, BB
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U31 - U31
  • [23] Differential effects of PPARγ agonist, insulin receptor activator, and metformin in a nongenetic mouse model of type 2 diabetes
    Strowski, MZ
    Li, ZH
    Szalkowski, DM
    Liu, F
    Shen, XL
    Moller, DE
    Zhang, BB
    DIABETES, 2001, 50 : A301 - A301
  • [24] Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody
    Hinke, Simon A.
    Cieniewicz, Anne M.
    Kirchner, Thomas
    D'Aquino, Katharine
    Nanjunda, Rupesh
    Aligo, Jason
    Perkinson, Robert
    Cooper, Philip
    Boayke, Ken
    Chiu, Mark L.
    Jarantow, Steve
    Lacy, Eilyn R.
    Liang, Yin
    Johnson, Dana L.
    Whaley, Jean M.
    Lingham, Russell B.
    Kihm, Anthony J.
    MOLECULAR METABOLISM, 2018, 10 : 87 - 99
  • [25] SUPPLEMENTATION AS A POTENTIAL INSULIN SENSITIZER OF HUMAN FAT THROUGH PPARγ ACTIVATION IN MENOPAUSAL WOMEN
    Sites, C. K.
    Feinland, J.
    Choi, Y.
    Discenza, I.
    Kim, Y-C
    FERTILITY AND STERILITY, 2013, 100 (03) : S337 - S337
  • [26] Insulin sensitizer prevents and ameliorates experimental type 1 diabetes
    Valitsky, Michael
    Hoffman, Amnon
    Unterman, Terry
    Bar-Tana, Jacob
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2017, 313 (06): : E672 - E680
  • [27] Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer
    Hu, L.
    Shen, H.
    Wu, Q. F.
    Tian, L.
    Hu, M. H.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2014, 41 (03): : 288 - 292
  • [28] Cardiac hypertrophy induced by PPAR-γ agonist treatment occurs independently of changes in myocardial insulin signaling
    Rasmussen, I
    McQueen, AP
    Zaha, VG
    Litwin, SE
    Berger, JP
    Abel, ED
    CIRCULATION, 2004, 110 (17) : 321 - 322
  • [29] Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-α agonist treatment
    Cree, Melanie G.
    Newcomer, Bradley R.
    Read, Laura K.
    Sheffield-Moore, Melinda
    Paddon-Jones, Douglas
    Chinkes, David
    Aarsland, Asle
    Wolfe, Robert R.
    MECHANISMS OF AGEING AND DEVELOPMENT, 2007, 128 (10) : 558 - 565
  • [30] Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes
    Piatkowska-Chmiel, Iwona
    Herbet, Mariola
    Gawronska-Grzywacz, Monika
    Dudka, Jaroslaw
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (10)
12345